The said acquisition is for a total consideration of Rs28.05 crore.
Shailesh Gadre, Founder of GCV Life was the exclusive advisor for the transaction
Post purchase of shares, the target entity would become a wholly owned subsidiary of SPL.
Alkem Lab, Pfizer, and Divis Lab were also among the top gainers. Cipla, Granules India, and Lupin were trading in the red.
The pharma company paid $99.279 million for the entire transaction.
The consideration for this acquisition is set as an upfront payment plus performance and milestone-based earn-outs over the next four years.
Their primary business activity is to invest funds with the objective of achieving appreciation of capital invested.
Their primary business activity is to invest funds to achieve an appreciation of the capital invested.
Further, before the proposed combination, GSKAPL will acquire the trademarks about “Iodex†and “Ostocalcium†brands in India .
Sun Pharma performed as top gainer surging by 3% after hitting 52-week high Rs861.50 per piece.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
